summarise this converstation into a checklist for work up and management of

Checklist for Investigation and Management of Raised Triglycerides

• Initial Assessment: Measure a non-fasting full lipid profile, including triglycerides, total cholesterol, HDL-C, calculated LDL-C and non-HDL cholesterol; consider fasting repeat if triglycerides between 10–20 mmol/L NICE CKS.
• Confirm Severity: Triglyceride levels guide management tiers:
  • Below 4.5 mmol/L: mild to moderate elevation
  • 4.5 to 9.9 mmol/L: moderate elevation, potentially underestimating cardiovascular risk
  • 10 to 20 mmol/L: significant hypertriglyceridemia requiring fasting repeat and secondary cause review
  • Above 20 mmol/L: severe hypertriglyceridemia necessitating urgent specialist referral NICE CKS.
• Screen for Secondary Causes: Investigate and manage secondary factors such as uncontrolled diabetes, hypothyroidism, excess alcohol, liver and kidney disease, obesity, and medications known to raise triglycerides (e.g., olanzapine, corticosteroids, beta-blockers, estrogen therapies, thiazide diuretics, protease inhibitors) NICE CKS,SmPC Lopid.
• Clinical History and Risk Factor Assessment: Assess cardiovascular risk using tools like QRISK3 or SCORE2-Diabetes; low 10-year risk (<10%) prioritizes lifestyle changes; higher risk may warrant lipid-lowering therapy NICE CKS,NICE NG238,Brandts et al. 2026.
• Baseline Investigations: Liver transaminases, renal function (eGFR), diabetes status (HbA1c), thyroid function if indicated, and creatine kinase if muscle symptoms present NICE CKS.
• Lifestyle Treatment: Emphasize weight loss (target 5-10% if overweight/obese), low saturated/trans fats, reduction of refined carbohydrates and sugars, limitation of alcohol, increased physical activity (≥150 min moderate or 75 min vigorous exercise weekly), and smoking cessation support NICE CKS,NICE NG238,Alam et al. 2026.
• Pharmacological Management:
  • Triglycerides below 4.5 mmol/L: focus on lifestyle; statins if overall cardiovascular risk (e.g., QRISK3) ≥10% or other lipid abnormalities present NICE CKS,NICE CKS,Alam et al. 2026.
  • Triglycerides 4.5–9.9 mmol/L: optimize management of other CVD risk factors and consider specialist advice if non-HDL cholesterol elevated NICE CKS.
  • Triglycerides ≥10 mmol/L: consider pharmacotherapy targeting triglycerides; fibrates or prescription omega-3 fatty acids (e.g., icosapent ethyl) used mainly to reduce pancreatitis risk alongside statins for CVD risk reduction NICE CKS,SmPC Lopid,SmPC Omega,Alam et al. 2026.
  • Severe hypertriglyceridemia (>20 mmol/L): urgent specialist referral; acute interventions may include intravenous insulin, plasmapheresis, and strict dietary fat restriction especially in genetic disorders NICE CKS,PubMed,Alam et al. 2026.
• Referral Criteria: Urgent referral for triglycerides above 20 mmol/L not due to secondary causes; specialist advice for levels between 10–20 mmol/L if persistent after repeat fasting measurement; consider familial lipid disorder evaluation if family history or clinical suspicion present NICE CKS,NICE CG71.
• Monitoring and Follow-up: Repeat lipid profiles and liver function 2–3 months after treatment initiation or adjustment; annual lipid monitoring with clinical review including adherence and lifestyle; monitor for statin side effects focusing on muscle symptoms NICE CKS,NICE NG238.
• Consider Emerging Therapies: Novel agents targeting apoC-III and ANGPTL3 inhibitors show promise in refractory cases or genetic hypertriglyceridemia but remain in specialist use pending further evidence Alam et al. 2026.

Summary: Management of raised triglycerides involves comprehensive cardiovascular risk stratification, exclusion of secondary causes—including medication review—and prioritization of lifestyle interventions. Pharmacological treatment targeting triglycerides is indicated primarily for levels ≥10 mmol/L or higher CVD risk. Urgent specialist referral is compulsory for triglycerides >20 mmol/L. Statin therapy remains foundational for lipid management aligned to cardiovascular risk. Emerging molecular therapies may reshape future approaches but require further validation NICE CKS,NICE CKS,Alam et al. 2026,Brandts et al. 2026.